Abcam & Cancer Research UK join forces to accelerate cancer research

By Akshay Kedari  Date: 2020-07-09

Abcam & Cancer Research UK join forces to accelerate cancer research

Cancer Research UK, one of the world's biggest independent funder of cancer research, has recently joined forces with Abcam plc, a leading developer of life science tools and reagents, to commercialize and develop novel custom antibodies to strengthen cancer research.

According to the terms of this partnership, Abcam would create custom protein-based reagents to targets that are recognized by researchers at Cancer Research UK. These antibodies would support the ongoing research and progress the understanding of cancer biology. Moreover, it would potentially be the basis for novel therapies as well as help generate new diagnostic tools.

Upon request, Abcam would deliver unique antibodies created during the terms of the agreement to researchers funded by Cancer Research UK for a pre-determined span of exclusivity in correspondence to that antibody. 

Meanwhile, Abcam’s co-location in key technology spots throughout the world and global supply capability would allow these innovative reagents to be easily available across wider diagnostic and research development community.

Speaking on the move, Tony Hickson, CBO, Cancer Research UK, said that the company is thrilled to collaborate with Abcam to develop tools that scientists require to help advance their understanding of cancer and to extend its access to biological reagents.

Additionally, Abcam’s “end-to-end” expertise and antibody development capabilities would support works of numerous researchers with antibody reagents that could be utilized from the initial stages of R&D right to the clinical trials.

As for Dr. John Baker, SVP of Product Portfolio Innovation, Abcam, the company is delighted to partner with Cancer Research UK to strengthen research by scientist and offer them easy access to validated and specific reagents, thereby helping them attain future breakthrough quickly.

Prior to this news, Abcam had made headlines when it announced that it has purchased assets of oncology product portfolio and gene editing platform from Applied StemCell, Inc. (ASC) for life science diagnostic and research markets. 
 

Source credit: https://www.abcam.com/index.html?pageconfig=news&rid=17091

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Williams Racing and Acronis extend their cyber protection partnership
Williams Racing and Acronis extend their cyber protection partnership
By Akshay Kedari

Williams Racing, a British Formula One motor racing team, has announced to have renewed its technology partnership with a Switzerland-based leading cyber protection and software company Acronis International GmbH. As a part of the Official Cyber Pro...

Tesla planning to set up EV manufacturing facility in Karnataka, India
Tesla planning to set up EV manufacturing facility in Karnataka, India
By Akshay Kedari

American electric car company Tesla Inc. has reportedly signed an agreement to manufacture its electric vehicles in Karnataka, India after announcing an entry into the South Asian country in 2021. The company had established its Indian subsidiary cal...

Pandemic forces Heineken to recoup profits by cutting 8000 jobs
Pandemic forces Heineken to recoup profits by cutting 8000 jobs
By Akshay Kedari

The Dutch brewing company, Heineken N.V., has recently revealed its plans to cut around 8000 jobs in an attempt to restore its operating margins after it witnessed a sharp decline in its profit trajectory amid the COVID-19 pandemic. Moreover, it will...

Indian software vendors accelerate shift to Oracle’s Cloud platform
Indian software vendors accelerate shift to Oracle’s Cloud platform
By Akshay Kedari

American multinational computer technology company Oracle Corp. reportedly stated that several independent software vendors (ISVs) from India including Medexpeert, GOFRUGAL, Information Dynamics, and Ameyo among others are shifting their business-cri...

Datomize raises USD 6 million through TPY Capital-led funding round
Datomize raises USD 6 million through TPY Capital-led funding round
By Akshay Kedari

Computer software startup Datomize, has reportedly raised USD 6 million in a seed funding round led by TPY Capital for expanding the capabilities of its synthetic data solution which shortens time to market for new products and machine learning/artif...